 Zynerba Pharmaceuticals NASDAQ:ZYNE Inc said it presented a poster on the long-term safety and efficacy of its cannabidiol transdermal gel, Zygel, at the 2022 Society of Biological Psychiatry SOBP Annual Meeting held in New Orleans, Louisiana, and virtually, from April 28-30, 2022. The poster, titled Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome FXS ZYN2-CL-017, showed Zygel was well-tolerated in long-term administration of up to 38 months of exposure in an ongoing safety and efficacy study of the drug in children and adolescents with FXS. 